A novel form of treatment that encourages the body's own immune system to recognize and eliminate cancer cells in the brain has achieved success, according to research done in test animals.
Highest risk seen for Latinos; estimated 26 percent of HCC cases in Latinos due to diabetes
The physiological reserves of elderly patients with cancer were evaluated and the most relevant biomarkers indicating their functional biological age were described in a recent publication by the Elderly Task Force of the European Organization for Research and Treatment of Cancer.
Inhibition of a molecule that occurs in some cancers with a poor prognosis as well as rheumatoid arthritis (RA) may lead to new treatments for both diseases.
Genomic and epigenomic alterations in the PAX gene family are associated with racial disparity in head and neck squamous cell carcinoma (HNSCC) survival, according to a study.
Practice management expert offers advice to clinicians for building a practical budget, despite the economic uncertainties of health care reform.
Tumor cells with mutated p53, which is mutated in about half of all cancers, can be made much more vulnerable to chemotherapy by blocking another gene called MK2.
When examined, circumferential resection margin predicts overall survival, disease-free survival, and local recurrence.
A new blood test for peptides cleaved by carboxypeptidase N may soon be available to help detect early stages of breast cancer.
The FDA approved obinutuzumab (Gazyva) or use in combination with chlorambucil to treat patients with previously untreated CLL, ibrutinib (Imbruvica) received FDA approval for the treatment of mantle cell lymphoma, and other FDA actions.
A screening mammography interval of less than 1.5 years is associated with a significantly reduced rate of lymph node positivity.
Mammographic density is associated with breast cancer among women younger than 50 years, according to a study.
Treatment of pelvic nodes individualized by inclusion of sentinel nodes can be easily integrated into an intensity-modulated radiation therapy (IMRT)-based treatment strategy, according to a new study.
An investigational new PARP inhibitor, BMN 673, is showing early responses in patients with heavily pretreated, advanced, BRCA-related cancers of the breast and ovary.
An investigational drug that disrupts tumor blood vessels shows promise against a rare type of pancreatic cancer, according to recently presented research.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|